All lobbying filings

Indivior Inc.

Indivior Inc. filed a Q3 report for Indivior Inc. on October 20, 2025.

Lobbying for Indivior Inc.

As filed: INDIVIOR INC for INDIVIOR INC.

All filings by Indivior Inc. · Everything Indivior Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$250,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Virginia

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

SUPPORT for Patients and Communities Reauthorization Act (HR 2483); HALT Fentanyl Act (HR 27 / S 331); Reentry Act (HR 2586); Due Process Continuity of Care Act (HR 1510); One Big Beautiful Bill Act (HR 1); FY26 appropriations for Labor-HHS-Education, Military Construction and Veterans Affairs, and Commerce-Justice-Science; DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40).

Bills named in this filing 5

H.R. 2483
SUPPORT for Patients and Communities Reauthorization Act of 2025
H.R. 27
HALT Fentanyl Act
H.R. 2586
Reentry Act of 2025
H.R. 1510
Due Process Continuity of Care Act
H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.